Financial Consulate’s AstraZeneca AZN Stock Holding History

Financial Consulate’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$165K	Sell	870 -3	-0.3%	-$564	0.02%	179
2026 Q1	$172K	Buy	873 +62	+8%	+$12K	0.02%	162
2025 Q4	$149K	Buy	811 +8	+1%	+$1.4K	0.02%	194
2025 Q3	$123K	Buy	+803	New	+$122K	0.02%	208

Other funds holding AZN

Evelyn Partners London $46.9B AUM

Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Financial Consulate's AZN Position: Q2 2026 in Review

Financial Consulate reduced its AstraZeneca (AZN) stake by 0.34% in Q2 2026, selling an estimated $564 and leaving 870 shares worth $165K. The position accounts for 0.02% of the portfolio, ranked #179.

Financial Consulate first reported a position in AZN in Q3 2025 and has held it in 4 quarters since. The position peaked at $172K in Q1 2026. 1,502 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

Financial Consulate held 870 shares of AstraZeneca worth $165K as of Q2 2026.
Financial Consulate sold 3 AstraZeneca shares in Q2 2026, an estimated $564.
AstraZeneca made up 0.02% of Financial Consulate's portfolio in Q2 2026, its #179 holding.
Financial Consulate first reported a position in AstraZeneca in Q3 2025 and has held it in 4 quarters since.
Financial Consulate's AstraZeneca position peaked at $172K in Q1 2026.
1,502 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Financial Consulate's 13F filing for Q2 2026, filed 23 Jul 2026.